$922 Million is the total value of VR Adviser, LLC's 28 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
TIL | New | INSTIL BIO INC | $172,176,000 | – | 6,865,076 | +100.0% | 18.68% | – |
CGEM | New | CULLINAN MANAGEMENT INC | $49,010,000 | – | 1,176,145 | +100.0% | 5.32% | – |
PHVS | New | PHARVARIS BV | $25,335,000 | – | 902,882 | +100.0% | 2.75% | – |
EPIX | New | ESSA PHARMA INC | $18,178,000 | – | 625,754 | +100.0% | 1.97% | – |
ACET | New | ADICET BIO INC | $13,080,000 | – | 1,000,000 | +100.0% | 1.42% | – |
New | APTOSE BIOSCIENCES INC | $9,592,000 | – | 1,605,400 | +100.0% | 1.04% | – | |
EYPT | New | EYEPOINT PHARMACEUTICALS INC | $7,112,000 | – | 700,000 | +100.0% | 0.77% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
ACLARIS THERAPEUTICS INC | 12 | Q3 2023 | 12.7% |
VIRIDIAN THERAPEUTICS INC | 12 | Q3 2023 | 13.4% |
COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.3% |
RELMADA THERAPEUTICS INC | 11 | Q3 2022 | 9.9% |
GH RESEARCH PLC | 10 | Q3 2023 | 6.7% |
ALTIMMUNE INC | 9 | Q3 2022 | 11.6% |
MARINUS PHARMACEUTICALS INC | 9 | Q4 2022 | 5.7% |
CELLDEX THERAPEUTICS INC | 9 | Q3 2022 | 7.6% |
AFFIMED N V | 8 | Q3 2023 | 1.1% |
INSTIL BIO INC | 7 | Q3 2022 | 18.7% |
View VR Adviser, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-11 |
13F-HR/A | 2023-05-15 |
13F-HR/A | 2023-05-15 |
13F-HR/A | 2023-05-15 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
View VR Adviser, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.